PRLD

Prelude Therapeutics Incorporated
CAPPED RATING

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

Prelude Therapeutics Incorporated (PRLD) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B-); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B-
Factor Score 2.9 / 5.0
Growth
D+
Factor Score 1.6 / 5.0
Profitability
C+
Factor Score 2.8 / 5.0
Momentum
C
Factor Score 2.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.9
EV / EBITDA -3.4
Rev Growth YoY N/A
Gross Margin N/M
Price Return 3M -38.7%
Price Return 12M 134.7%
Catalyst Signal 0.00
Market Cap $274.8M
TTM Revenue $22.4M
Price / Sales 12.3
ROE -57.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B- (2.9) D+ (1.6) C+ (2.8) C (2.2) C+ (2.6) C (2.4)
2026-11-07 B- (2.9) D+ (1.6) C+ (2.8) C (2.4) C+ (2.7) C (2.5)
2026-10-31 B- (2.9) D+ (1.6) B- (3.0) C (2.5) C+ (2.7) C+ (2.5)
2026-10-24 B- (2.9) D+ (1.6) B- (2.9) C+ (2.5) C+ (2.6) C+ (2.5)
2026-10-17 B- (3.0) D+ (1.6) B- (2.9) C+ (2.6) C+ (2.6) C+ (2.6)
Page 1 of 5